Oncopeptides carries out a 300 million SEK rights issue
Find more information including questions and answers here.
Link to rights issue page, Oncopeptalks, Q&A for investors and recorded webcast
Sofia Heigis participated at Invest in Oncology Forum
April 11, 2024 – Sofia Heigis recently presented Oncopeptides at the Invest in Oncology Forum, organized by Cord Communications. The presentation was followed by a Q&A session where a number of professional investors and clinical experts were invited to ask questions.
Oncopeptides held investor presentation at ProHearings
April 10, 2024 – Oncopeptides’ CEO Sofia Heigis recently presented the company to ProHearings, an independent channel for information to investors.
Company news
Oncopeptides secures national reimbursement for Pepaxti in Spain
April 15, 2024
Oncopeptides AB announces the approval of price and reimbursement allowing Oncopeptides to start commercializing its flagship drug Pepaxti in Spain as early as in 2024. Preparations ongoing with full launch expected to commence after summer.
Read more
Oncopeptalks on Q1 sales and MENA partnership
April 4, 2024
Sofia Heigis, CEO discusses recent news in the latest edition of Oncopeptalks.
Read moreOncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa
March 27, 2024
Oncopeptides AB and Vector Pharma FZCO (“Vector”) today announced a collaboration to commercialize Oncopeptides’ flagship drug Pepaxti (melphalan flufenamide) in the Middle East and North Africa (“MENA”).
Read moreScience news
Oncopeptides’ PORT study shows peripheral administration of Pepaxti being equally safe as central venous administration
March 1, 2024
Oncopeptides today announces that a new article analyzing scientific data on melflufen, marketed in Europe as Pepaxti, was recently published in the peer-reviewed medical journal Clinical Lymphoma, Myeloma and Leukemia.
Read morePepaxti provides sustained health related Quality of Life OCEAN study shows, article published in Haematologica
February 29, 2024
Oncopeptides today announces that a new article analyzing health-related quality of life in patients treated with melflufen, marketed in Europe as Pepaxti, has been published in Haematologica.
Read moreType IB variation process finalized – original indication remains with peripheral administration included
February 7, 2024
Oncopeptides recently received a favorable opinion from EMA to revert back to the originally approved indication for Pepaxti. This means that the previously communicated decision to opt out of the process to extend the indication has now been fully realized.
Read moreInvestor news
Sofia Heigis participated at Invest in Oncology Forum
April 11, 2024
Sofia Heigis recently presented Oncopeptides at the Invest in Oncology Forum, organized by Cord Communications. The presentation was followed by a Q&A session.
Read more
Oncopeptides held investor presentation at ProHearings
April 10, 2024
Oncopeptides' CEO Sofia Heigis recently presented the company to ProHearings, an independent channel for information to investors. Watch the presentation.
Read more
Biostock investor pitch: Oncopeptides
March 22, 2024
Sofia Heigis, CEO, presents Oncopeptides to BioStock, Scandinavia’s leading digital news and analysis service with an exclusive focus on companies in the Life Science sector.
Read morePress release - April 17, 2024
Oncopeptides publishes prospectus relating to the rights issue
Read press release
Released February 27, 2024
Oncopeptides publishes year-end report 2023
Download
“The fourth quarter sets the stage for revenue acceleration in 2024”
CEO Sofia Heigis
See the Webcast
For further information, please contact:
David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68
Oncopeptides AB Q1 interim report 2024 will be published May 30, 2024
Upcoming events
2024-04-22
Annual report 2023
Report
2024-04-29 - 2024-05-29
Silent Period
Other
2024-05-30
Interim Report Q1 2024
Report
Vision of Oncopeptides
”Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”
Cultures & Values
We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.